While the newly formed AbbVie (ABBV +0.04%) may seem to have a lot of debt on its balance sheet, it's important for investors to take that debt in context. In this video, Motley Fool health-care bureau chief Brenton Flynn discusses AbbVie's debt in relation to some of its peers and tells us why the company's cash on hand, the low cost of that debt, and the time to maturity are all factors that mean the company's debt isn't as big of a concern as it may seem to investors hoping for dividend growth.
